{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T03:19:56Z","timestamp":1785727196065,"version":"3.56.0"},"reference-count":77,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-00170\/24-00"],"award-info":[{"award-number":["2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-00170\/24-00"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"award":["2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-00170\/24-00"],"award-info":[{"award-number":["2024\/ABM\/03\/KPO\/KPOD.07.07-IW.07-00170\/24-00"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The qualitative detection of circulating tumor human papillomavirus DNA (ctHPV) has shown promise in HPV-associated cancers. We performed a systematic review and meta-analysis to evaluate the association of pretreatment ctHPV levels with survival outcomes and quantitative tumor burden metrics. Databases were searched through 5 January 2026. Studies were eligible if they included patients with HPV-associated cancers and reported quantitative pretreatment ctHPV levels in relation to survival outcomes or tumor burden. Twenty-three studies were included in the quantitative synthesis. Higher pretreatment ctHPV levels were associated with poorer progression-free survival (PFS) (8 studies, n = 883; HR = 1.86, 95% CI 1.19\u20132.90; p = 0.013). This association was primarily driven by studies in oropharyngeal cancer (OPC; HR = 2.47, 95% CI 1.59\u20133.84; p = 0.007), whereas no significant association was observed in cervical cancer. In multivariable analyses, elevated ctHPV remained associated with shorter PFS (HR = 1.87, 95% CI 1.66\u20132.10; p = 0.002). No significant association was observed for overall survival. Pretreatment ctHPV correlated with nodal volume in OPC (r = 0.45), nodal and tumor volume in OPC\/anal cancer (r = 0.39), primary tumor volume in OPC (r = 0.22), and tumor diameter in cervical cancer (r = 0.44). Higher pretreatment ctHPV levels are associated with greater tumor burden and poorer PFS in HPV-associated OPC. CtHPV shows potential as a prognostic biomarker, although further prospective studies and assay standardization are needed.<\/jats:p>","DOI":"10.3390\/ijms27104263","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T07:49:09Z","timestamp":1778572149000},"page":"4263","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Value of Pretreatment Circulating Tumor HPV DNA Load in HPV-Associated Cancers: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"27","author":[{"given":"Iwona Agnieszka","family":"Jab\u0142o\u0144ska","sequence":"first","affiliation":[{"name":"Clinical Trials Support Centre, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7891-672X","authenticated-orcid":false,"given":"Marcin","family":"Go\u0142awski","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-8464","authenticated-orcid":false,"given":"Dorota","family":"\u015aciegli\u0144ska","sequence":"additional","affiliation":[{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Department of Biotechnology and Nutrigenomics, Institute of Genetics and Animal Biotechnology of the Polish Academy of Science, Postepu 36A St., Jastrzebiec, 05-552 Magdalenka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0415-5683","authenticated-orcid":false,"given":"Urszula","family":"Kacorzyk","sequence":"additional","affiliation":[{"name":"I Radiation and Clinical Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Wojciuszkiewicz","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Centre, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz Wojciech","family":"Rutkowski","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Centre, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6545-4095","authenticated-orcid":false,"given":"Agnieszka Maria","family":"Mazurek","sequence":"additional","affiliation":[{"name":"Clinical Trials Support Centre, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"},{"name":"Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-102 Gliwice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"1659","article-title":"DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells","volume":"61","author":"Jahr","year":"2001","journal-title":"Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-23-1478","article-title":"Negative predictive value of circulating tumor tissue modified viral (TTMV)-HPV DNA for HPV-driven oropharyngeal cancer surveillance","volume":"29","author":"Hanna","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-24-3053","article-title":"A prospective trial of biomarker-guided surveillance for HPV-positive oropharynx cancer using plasma tumor tissue-modified viral HPV DNA","volume":"31","author":"Rettig","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-21-0625","article-title":"Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer","volume":"27","author":"Jeannot","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12967-020-02330-y","article-title":"Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer","volume":"18","author":"Rutkowski","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1158\/1078-0432.CCR-18-2984","article-title":"Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: An ancillary study to the Epitopes-HPV02 trial","volume":"25","author":"Jeannot","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e008436","DOI":"10.1136\/jitc-2023-008436","article-title":"Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: Analysis of a phase II clinical trial and a cohort of long-term responders","volume":"12","author":"Huffman","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1158\/1078-0432.CCR-23-3941","article-title":"Cell-free human papillomavirus DNA is a sensitive biomarker for prognosis and for early detection of relapse in locally advanced cervical cancer","volume":"30","author":"Sivars","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12597","DOI":"10.1007\/s00432-023-05077-3","article-title":"Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer","volume":"149","author":"Thangarajah","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Mazurek, A.M., Jab\u0142o\u0144ska, I., Kentnowski, M., Kacorzyk, U., \u015anietura, M., and Rutkowski, T.W. (2024). Pretreatment Circulating HPV16 DNA Viral Load Predicts Risk of Distant Metastasis in Patients with HPV16-Positive Oropharyngeal Cancer. Cancers, 16.","DOI":"10.3390\/cancers16061163"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"109773","DOI":"10.1016\/j.radonc.2023.109773","article-title":"Circulating tumour HPV16 DNA quantification\u2014A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy","volume":"186","author":"Adrian","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12105-025-01752-8","article-title":"Development and Validation of an Assay to Quantify Plasma Circulating Tumor Human Papillomavirus DNA for 13 High-Risk Types that Cause 98% of HPV-Positive Cancers","volume":"19","author":"Wotman","year":"2025","journal-title":"Head Neck Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"100154","DOI":"10.1016\/j.esmoop.2021.100154","article-title":"HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer","volume":"6","author":"Cabel","year":"2021","journal-title":"ESMO Open"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lef\u00e8vre, A.C., Pallisgaard, N., Kronborg, C., Wind, K.L., Krag, S.R.P., and Spindler, K.-L.G. (2021). The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus. Cancers, 13.","DOI":"10.3390\/cancers13102451"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Jab\u0142o\u0144ska, I., Go\u0142awski, M., Wojciuszkiewicz, N., \u015aci\u0119gli\u0144ska, D., Kacorzyk, U., and Mazurek, A.M. (2025). The Prognostic Utility of Quantitative Circulating Tumor HPV DNA in Cancer Patients: A Systematic Review and Meta-Analysis. PROSPERO, CRD42025627557.","DOI":"10.3390\/ijms27104263"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"659","DOI":"10.4143\/crt.2022.1440","article-title":"Plasma Cell-Free DNA in Uterine Cervical Cancer: Therapeutic Monitoring and Prognostic Values after Radical Radiotherapy","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jcv.2019.03.005","article-title":"Liquid biopsy of HPV DNA in cervical cancer","volume":"114","author":"Cheung","year":"2019","journal-title":"J. Clin. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1158\/2767-9764.CRC-25-0180","article-title":"Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy","volume":"5","author":"Echevarria","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101755","DOI":"10.1016\/j.ijgc.2025.101755","article-title":"Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer","volume":"35","author":"Collier","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"RP101887","DOI":"10.7554\/eLife.101887","article-title":"Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: Clinical significance and treatment implications","volume":"13","author":"Yin","year":"2025","journal-title":"eLife"},{"key":"ref_24","unstructured":"Rohatgi, A. (2026, April 06). WebPlotDigitizer, Available online: https:\/\/automeris.io\/WebPlotDigitizer."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/jrsm.1654","article-title":"Meta-analyzing partial correlation coefficients using Fisher\u2019s z transformation","volume":"14","year":"2023","journal-title":"Res. Synth. Methods"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2004","journal-title":"Biometrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_29","unstructured":"National Heart, Lung, and Blood Institute (2026, April 06). Study Quality Assessment Tools, Available online: https:\/\/www.nhlbi.nih.gov\/health-topics\/study-quality-assessment-tools."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/j.ijrobp.2011.05.061","article-title":"Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients","volume":"82","author":"Cao","year":"2012","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/hed.28180","article-title":"Artificial Intelligence Measured Tumor Burden and Pre-Treatment Circulating Tumor DNA in Human Papilloma Virus-Associated Oropharynx Cancer","volume":"47","author":"Bakhtiar","year":"2025","journal-title":"Head Neck"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoto.2024.5549","article-title":"Pretreatment Liquid Biopsy and Clinicopathologic Features in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","volume":"151","author":"Cooke","year":"2025","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"107179","DOI":"10.1016\/j.oraloncology.2025.107179","article-title":"Circulating tumor DNA determines induction chemotherapy response in HPV-associated oropharyngeal squamous cell carcinoma: A pilot study","volume":"161","author":"Huttinger","year":"2025","journal-title":"Oral Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/ohn.1345","article-title":"Circulating Tumor Tissue-Modified-Viral HPV DNA and Correlations With Disease Burden in Oropharyngeal Cancer","volume":"173","author":"Lee","year":"2025","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1001\/jamaoto.2023.1730","article-title":"Lead Time to Recurrence After Posttreatment Plasma and Saliva HPV DNA Testing in Patients With Low-Risk HPV Oropharynx Cancer","volume":"149","author":"Califano","year":"2023","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1093\/annonc\/mdy251","article-title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer","volume":"29","author":"Hanna","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma","volume":"28","author":"Cao","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"21226","DOI":"10.1038\/s41598-023-48506-6","article-title":"Determinants of the level of circulating-tumor HPV16 DNA in patients with HPV-associated oropharyngeal cancer at the time of diagnosis","volume":"13","author":"Kentnowski","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/hed.27866","article-title":"Circulating tumor HPV DNA in the management of HPV+ oropharyngeal cancer and its correlation with MRI","volume":"46","author":"Campo","year":"2024","journal-title":"Head Neck"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.oraloncology.2019.06.019","article-title":"Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer","volume":"95","author":"Hanna","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1001\/jamaoto.2024.0350","article-title":"Preoperative Circulating Tumor HPV DNA and Oropharyngeal Squamous Cell Disease","volume":"150","author":"Lam","year":"2024","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Lee, J.Y., Cutts, R.J., White, I., Augustin, Y., Garcia-Murillas, I., Fenwick, K., Matthews, N., Turner, N.C., Harrington, K., and Gilbert, D.C. (2020). Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00505"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.annonc.2025.05.533","article-title":"Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: Phase III CALLA trial analyses","volume":"36","author":"Mayadev","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"11480","DOI":"10.1038\/s41598-025-93152-9","article-title":"Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy","volume":"15","author":"Gupta","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s10147-025-02762-w","article-title":"Utility of circulating human papillomavirus DNA as a biomarker for detection and prognosis of cervical cancer in Japanese patients","volume":"30","author":"Taguchi","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s40291-025-00809-2","article-title":"Human Papillomavirus Type and Viral Load in Relation to Circulating Cell-Free Tumour HPV DNA Level and Survival in Cervical Cancer","volume":"29","author":"Hellman","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1158\/1078-0432.CCR-24-2343","article-title":"Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation","volume":"31","author":"Seo","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Campitelli, M., Jeannot, E., Peter, M., Lappartient, E., Saada, S., de la Rochefordi\u00e8re, A., Fourchotte, V., Alran, S., Petrow, P., and Cottu, P. (2012). Human papillomavirus mutational insertion: Specific marker of circulating tumor DNA in cervical cancer patients. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0043393"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2005.07.004","article-title":"Detection and quantitation of human papillomavirus type 16, 18 and 52 DNA in the peripheral blood of cervical cancer patients","volume":"99","author":"Ho","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"B\u00f8nl\u00f8kke, S., Stougaard, M., Sorensen, B.S., Booth, B.B., H\u00f8gdall, E., Nyvang, G.-B., Lindegaard, J.C., Blaak\u00e6r, J., Bertelsen, J., and Fuglsang, K. (2022). The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients. Cells, 11.","DOI":"10.3390\/cells11142170"},{"key":"ref_51","first-page":"2170","article-title":"Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy","volume":"3","author":"Damerla","year":"2019","journal-title":"JCO Precis. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/cjp2.47","article-title":"Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma","volume":"2","author":"Jeannot","year":"2016","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41598-024-53894-4","article-title":"Association of circulating tumor HPV16DNA levels and quantitative PET parameters in patients with HPV-positive head and neck squamous cell carcinoma","volume":"14","author":"Tatsumi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ijgo.16011","article-title":"Circulating tumor HPV DNA as a specific biomarker for cervical cancer","volume":"169","author":"Chen","year":"2025","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/coa.14317","article-title":"Circulating Tumour DNA as a Complementary Tool for Treatment Evaluation in HPV-Associated Head and Neck Squamous Cell Carcinoma: An Observational Cohort Study","volume":"50","author":"Waenerlund","year":"2025","journal-title":"Clin. Otolaryngol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/s41418-024-01272-y","article-title":"Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck","volume":"31","author":"Zou","year":"2024","journal-title":"Cell Death Differ."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/bjc.2017.258","article-title":"Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma","volume":"117","author":"Lee","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jamaoto.2022.3282","article-title":"Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer","volume":"148","author":"Rettig","year":"2022","journal-title":"JAMA Otolaryngol. Head Neck Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"17592","DOI":"10.1002\/cam4.6377","article-title":"Predictive impact of human papillomavirus circulating tumor DNA in treatment response monitoring of HPV-associated cancers; a meta-analysis on recurrent event endpoints","volume":"12","author":"Karimi","year":"2023","journal-title":"Cancer Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s13046-024-03137-1","article-title":"The landscape of circulating tumor HPV DNA and TTMV-HPVDNA for surveillance of HPV-oropharyngeal carcinoma: Systematic review and meta-analysis","volume":"43","author":"Campo","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"107262","DOI":"10.1016\/j.oraloncology.2025.107262","article-title":"Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review","volume":"164","author":"Chennareddy","year":"2025","journal-title":"Oral Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1002\/cncr.29538","article-title":"Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer","volume":"121","author":"Dahlstrom","year":"2015","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s11864-022-00950-8","article-title":"HPV as a Carcinomic Driver in Head and Neck Cancer: A De-escalated Future?","volume":"23","author":"Bates","year":"2022","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.34109","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer","volume":"128","author":"Siravegna","year":"2022","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/hed.23697","article-title":"Staging and treatment of oropharyngeal cancer in the human papillomavirus era","volume":"37","author":"Ward","year":"2015","journal-title":"Head Neck"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cncr.29022","article-title":"A multi-institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensity-modulated radiotherapy","volume":"121","author":"Setton","year":"2015","journal-title":"Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1002\/cncr.29402","article-title":"Changing prognostic significance of tumor stage and nodal stage in patients with squamous cell carcinoma of the oropharynx in the human papillomavirus era","volume":"121","author":"Keane","year":"2015","journal-title":"Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/1940-6207.CAPR-19-0098","article-title":"Increasing Incidence rates of Oropharyngeal Squamous Cell Carcinoma in Germany and Significance of Disease Burden Attributed to Human Papillomavirus","volume":"12","author":"Wittekindt","year":"2019","journal-title":"Cancer Prev. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2886","article-title":"Human papillomavirus oncoproteins: Pathways to transformation","volume":"10","author":"Moody","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: Towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00405-020-05979-9","article-title":"A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status","volume":"277","author":"Majchrzak","year":"2020","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40134-013-0036-6","article-title":"Radiologic Assessment of Lymph Nodes in Oncologic Patients","volume":"2","author":"Mao","year":"2014","journal-title":"Curr. Radiol. Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jmoldx.2023.11.007","article-title":"Comparing the Diagnostic Performance of Quantitative PCR, Digital Droplet PCR, and Next-Generation Sequencing Liquid Biopsies for Human Papillomavirus-Associated Cancers","volume":"26","author":"Naegele","year":"2024","journal-title":"J. Mol. Diagn."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.23.00954","article-title":"Clinical Validation of Human Papilloma Virus Circulating Tumor DNA for Early Detection of Residual Disease After Chemoradiation in Cervical Cancer","volume":"42","author":"Han","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e2200494","DOI":"10.1200\/PO.22.00494","article-title":"Clearance Profile of Circulating Tumor Human Papillomavirus DNA During Radiotherapy Predicts Clinical Outcomes in Human Papillomavirus-Related Oropharyngeal Cancer","volume":"7","author":"Tanaka","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4263\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T04:21:37Z","timestamp":1778646097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":77,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104263"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104263","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]}}}